OMNOVA Solutions Inc (NYSE:OMN) announced that fiscal Q1 net loss was $0.2 million or breakeven a share, evaluated against a net income of $13.5 million or $0.29 a share for the first three months period of 2012.
This quarter comprised a loss from discontinued operations of $0.4 million, contrasted against an income from discontinued operations of $2.8 million or $0.06 a diluted share in fiscal Q1 of 2012.
Quarterly income from continuing operations was $0.2 million or breakeven a share, compared with $10.7 million or $0.23 a share for fist three months period.
At the current trading session, OMNOVA Solutions Inc (NYSE:OMN) shares are down -1.06% to $674.56 while the stocks are trading within the range of $669.70 – $684.63. In the past year, the stock has traded within a range of $556.52 – $774.38. The current session’s volume of 9.40 million shares is lower from their average daily trading volume of 4.16 million shares.
Obagi Medical Products, Inc (NASDAQ:OMPI) stock hiked over 9% to settle at $25.02 in premarket session following the report that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has lifted its offer to purchase the firm from $19.75 to $24.00 a share in cash, trumping Merz Pharma Group’s $22 a share bid.
Board of directors has unanimously approved the amended deal with Valeant.
Obagi Medical Products, Inc (NASDAQ:OMPI) shares are up +9.40% to $25.03 while the stock is trading within the range of $24.90 – $25.20 in the current trading session. In the last 12 months the shares have traded between $10.70 and $25.20. The current session’s volume of 493,412.00 shares is lower from their average daily trading volume of 888,845.00 shares.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL